- Q3 miss driven by Thebalux seasonality - EBITA growth of 21% y-o-y - Share trading at 8x '25e EV/E...
- Cyclical, variable volumes behind miss & soft near-term outlook - We cut '25e and '26e adj.
- Q3 EBITA 3% above IR consensus, 5% above ABGSCe - Focus on continued strong trend in Medical Solut...
- Strong performance in product companies behind EBITA beat.
- Minor estimate changes - Solid profitability ahead as growth conditions stall - EV/ARR 1.
Förvaltningsresultat ökade i perioden med 21% drivet av förvärvet av grannfastigheten i Poznan i jun...
Carlsquare Equity Research har publicerat sina första intryck efter Enrads nyligen offentliggjorda k...
Dovre’s EUR 2.4m EBIT was soft relative to our estimate despite the high top line, but in our view v...
Consti's net sales in Q3 amounted to EUR 86.0m, slightly above our estimates (Evli est.
SRV’s Q3/24 was broadly in line with our estimates.
Redeye retains its positive view of Avensia following a solid Q3 report with a healthy underlying ma...
- FY sales SEK 2.1-2.2bn (prev. 2.4bn), EBITA margin 6% (prev.
- Weak on sales but higher gross margin - More restrucrings to come - Estimates likely up 5-10% on a...
- Pre-announces Q3 sales 5% below ABGSCe... - ... and ~7% below on adj.
- 9% organic growth (ABG 9%) and EBITA -6% vs ABG - Positive development in all markets, Systems gre...
